

Form PTO 1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER P32085	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 09/743209	
INTERNATIONAL APPLICATION NO. PCT/GB99/02301		INTERNATIONAL FILING DATE 15 July 1999		PRIORITY DATE CLAIMED 17 July 1998	
TITLE OF INVENTION PROCESS FOR PREPARING CLAVAM DERIVATIVES BY USING POLYPEPTIDES HAVING BETA-LACTAM SYNTHETASE ACTIVITY					
APPLICANT(S) FOR DO/EO/US Barry BARTON, Heather Jane MCNAUGHTON, Christopher Joseph SCHOFIELD, and Jan Edward THIRKETTLE					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:


11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
 - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
 - ☐ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/GB99/02301, filed 15 July 1999, which claims benefit from the following Provisional Application: GB 9815666.4 filed 17 July 1998.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Sequence listing, Statement to Support, diskette

US APPLICATION NO. (if not in 37 CFR 1.50) 09/74089		INTERNATIONAL APPLICATION NO. PCT/GB99/02301		ATTORNEYS DOCKET NO. P32085	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):					
Search Report has been prepared by the EPO or JPO \$860.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) \$690.00					
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00					
Neither International Preliminary Examination Fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,000.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$0.00	
Claims	Number Filed	Number Extra	Rate		
Total claims	14 - 20 =	0	0 x \$18.00	\$0.00	
Independent claims	2 - 3 =	0	0 x \$80.00	\$0.00	
Multiple dependent claims (if applicable)			+ \$270.00	\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$270.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$1130.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				\$	
TOTAL NATIONAL FEE =				\$1130.00	
				Amount to be refunded	\$
				charged	\$

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$1130.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
SMITHKLINE BEECHAM CORPORATION
 Corporate Intellectual Property - UW2220
 P.O. Box 1539
 King of Prussia, PA 19406-0939
 Phone (610) 270-5024
 Facsimile (610) 270-5090


 SIGNATURE
 Zoltan Kerekes
 NAME
 38,938
 REGISTRATION NO.

Attorney Docket No. P32085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barton, et al.

08 January 2001

International App. No.: PCT/GB99/02301

Group Art Unit No.: Unknown

International Filing Date: 15 July 1999

Examiner: Unknown

For: NOVEL COMPOSITION

Assistant Commissioner of Patents

Box: PCT

Washington, D.C. 20231

PRELIMINARY AMENDMENT


Preliminary to the examination of this application, applicants respectfully request amendment of the above-identified application as follows:

IN THE CLAIMS:


Please cancel claims 1-14.

Please add new claims 15- 28.


15. A process for preparing compounds of formula (I)



wherein R is H or OH and R¹ is




or



and where R² = H or C₁₋₆ alkyl


by contacting a compound of formula (II)




where the variables are as defined in formula (I)

with a polypeptide having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

16. A process for preparing a compound of formula (IV)



by contacting N²-(2-carboxyethyl)-(S)-arginine; formula (III)



with a polypeptide having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

17. A process according to claim 15 or 16 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.

18. A process according to claim 15 or 16 wherein the polypeptide has the amino acid sequence of SEQ ID NO:2.

19. A process according to claim 15 or 16 wherein the polypeptide having β -lactam synthetase activity is obtainable from *Streptomyces* species.
20. A process according to claim 19 wherein the *Streptomyces* species is *Streptomyces clavuligerus*.
21. A recombinant vector comprising a polynucleotide capable of producing the polypeptide defined in claim 15 when said vector is present in a compatible host.
22. A recombinant vector according to claim 21 comprising a polynucleotide selected from the group:
- a) a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;
 - b) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:1; or
 - c) a polynucleotide having the polynucleotide sequence of SEQ ID NO:1.
23. A process according to claim 15 or 16 wherein the polypeptide is expressed from a recombinant vector comprising a polynucleotide capable of producing a polypeptide having at least 95% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity, when said vector is present in a compatible host.
24. A host microorganism containing a recombinant vector of claims 21 or 22.
25. A host microorganism according to claim 24 which is selected from *Streptomyces*, or *E.coli*.
26. A process for preparing an enzyme having β -lactam synthetase activity which comprises the steps:
- a) culturing *Streptomyces clavuligerus*,
 - b) harvesting and lysing the mycelium, and

c) isolating a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

27. A process for preparing an enzyme having β -lactam synthetase activity which comprises the steps:

a) culturing a host microorganism transformed with a recombinant vector according to claims 21 or 22, and

b) isolating the polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

28. A process for preparing clavulanic acid comprising preparing a compound of formula (IV) in accordance with claim 16 or any claim dependent thereon, and then converting the compound of formula (IV) to clavulanic acid by treatment with an enzyme system derived from *Streptomyces clavuligerus*.

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/GB99/02301.

Applicants have cancelled claims 1-14 and added new claims 15-28 to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes
Attorney for Applicants
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5024
Facsimile (610) 270-5090
N:\zk\apps\p32085\Preamd.doc

"EXPRESS MAIL CERTIFICATE"
"EXPRESS MAIL" MAILING LABEL NUMBER EL421190155US
DATE OF DEPOSIT: 08 January 2001

Attorney Docket No.: P32085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barton, et al. January 08, 2001
Serial No.: PCT/GB99/02301 Group Art Unit No.: Unknown
Filed: 15 July 1999 Examiner: Unknown
For: "Process for Preparing Clavam Derivatives by Using Polypeptides
Having Beta-Lactam Synthetase Activity

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825**

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, D.C. 20231

- (X) I hereby state that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**, respectively, are the same.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 CFR §1.825 (a)**, included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages _____. I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.

09743209 10501 60254260

PROCESS FOR PREPARING CLAVAM DERIVATIVES BY USING POLYPEPTIDES HAVING BETA-LACTAM SYNTHETASE ACTIVITY

The present invention relates to a new process for the synthesis of clavam
5 compounds, in particular clavulanic acid. In one aspect the invention relates to β -lactam
synthetase polypeptides and β -lactam synthetase polynucleotides, recombinant materials
thereof and methods for their production. In another aspect, the invention relates to
methods for using such polypeptides and polynucleotides.

A common feature of all penicillins and cephalosporins is the presence of a β -
10 lactam ring which is vital to their antibiotic activity. β -lactam compounds are susceptible
to degradation by β -lactamase enzymes which are produced by several clinically
important microorganisms. The ability of these microorganisms to produce β -lactamase
activities is a major factor in the spread of antibiotic resistance among clinically relevant
microorganisms.

15 Clavulanic acid, which also comprises a β -lactam ring, is a potent inhibitor of β -
lactamases and has been used successfully in combination with β -lactam antibiotics in
the treatment of infections caused by β -lactamase producing microorganisms. Clavulanic
acid is Z-(2R,5R)-3-(β -hydroxy- ethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]
heptane-2-carboxylic acid.

20 An understanding of the biosynthesis of these β -lactam molecules is central to
improvements in the manufacture of existing antibiotics, for example Augmentin (Trade
Mark of SmithKline Beecham plc), and for designing novel antibacterial compounds.
Although the biosynthetic pathways of penicillins and cephalosporins are well studied,
much remains to be learned about the biosynthesis of clavulanic acid.

25 Several steps in the clavulanic acid biosynthetic pathway have been elucidated,
predominantly those within the central part of the pathway, and in some cases their
corresponding enzymatic activities have been identified. These enzymatic activities have
been the subject of several publications and patent applications, for example EP 0349121
concerns clavamate acid synthase, WO 95/03416 discloses the enzyme clavulanic acid
30 dehydrogenase and WO 94/12654 the proclavamate amidinohydrolase.


It has been shown that in *Streptomyces clavuligerus*, a clavulanic acid producing
organism, the genes responsible for the biosynthesis of clavulanic acid are clustered

together close to the gene cluster involved in the biosynthesis of the penicillin and cephalosporin molecules which are also produced by this organism (Jensen, SE et al, 1993, Industrial Microorganisms, Basic and Applied Molecular Genetics, p169-176; American Society for Microbiology). The DNA sequence and predicted open reading
 5 frames for the clavulanic acid biosynthesis cluster are disclosed in Canadian patent application no. 2108113. This patent application discloses an 11.6kb fragment which encompasses 8 open reading frames (orf2 to orf9), which, when introduced into a non-clavulanic acid producing *Streptomyces* strain, confers the ability to produce clavulanic acid. The functions of some of the proteins predicted to be encoded by these orfs have
 10 been deduced based on known activity (eg. orf 5 is known to encode clavamate synthase II; Marsh et al, 1992, Biochem, 31 p12648-12657) or by similarity with known proteins (eg. orf2 shows a high level of homology with acetohydroxyacid synthase (Canadian patent application no. 2108113)). Some proteins, however, remain of unknown function.


15 The present invention is based on the finding that the orf3 gene encodes an enzyme that is alone capable of the conversion of the β -amino acid (formed from arginine and pyruvate) into the β -lactam form, early in the clavulanic acid biosynthesis pathway.

The polynucleotide sequence of orf3 is given in SEQ ID NO:1 and the
 20 polypeptide encoded by orf3 is given in SEQ ID NO:2; both sequences are disclosed in Canadian patent application no. 2108113.

Accordingly the present invention provides a process for preparing a β -lactam compound of formula (I) or salt thereof




30 wherein R is H or OH and R¹ is



and where $\text{R}^2 = \text{H}$ or C_{1-6} alkyl

by contacting a β -amino acid compound of formula (II) or salt thereof

5



where the variables are as defined in formula (I)

with a polypeptide having at least 95% identity to the amino acid sequence of SEQ ID


10 NO:2, over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

Compounds of formula (I) can be converted thereafter to clavulanic acid or other clavams compounds by conventional means. By 'other clavams' we mean compounds containing a 7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane nucleus [J.C.S., Chem. Commun. (1979), 282].

15 In a further aspect the compound of formula (I), prepared in accordance with the process of the invention, is converted to other clavams and clavam derivatives by treatment with an enzyme system derived from *Streptomyces clavuligerus*.


In a preferred embodiment the process concerns contacting a β -amino acid compound of formula (III) with said polypeptide having β -lactam synthetase activity.

20 The compound of formula (III) is N^2 -(2-carboxyethyl)-(S)-arginine first disclosed in WO 94/12654. Methods for the production of a compound of formula (III) are disclosed in WO 94/12654.



Contacting a compound of formula (III) with a polypeptide having β -lactam synthetase enzyme results in the closure of the β -lactam ring to give a β -lactam compound of

5 formula (IV), which is (2S)-5-guanidino-2-(2-oxo-azetidin-1-yl)pentanoic acid.



10 In a preferred aspect the compound of formula (IV), prepared in accordance with the process of the invention, is converted to clavulanic acid by treatment with an enzyme system derived from *Streptomyces clavuligerus*. The enzyme system includes the enzymes of the clavulanic acid biosynthetic pathway, for example clavaminic acid synthase (Baldwin, JE et al, J.Chem.Soc.,Chem.Comm. 500); proclavaminic acid

15 amidinohydrolase (disclosed in WO 94/12654); clavulanic acid dehydrogenase (disclosed in WO 95/03416) or any one, or combinations of, the enzymes encoded by the clavulanic acid biosynthesis gene cluster disclosed in Canadian patent application no. 2108113.

Such enzymes may be provided in isolated form, in recombinant hosts transformed with cloned genes encoding the enzymes or by contact with *Streptomyces*

20 *clavuligerus* whole cells.

The polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 will herein be referred to as β -lactam synthetase. The β -lactam synthetase preferably has 97-99% identity with the amino acid sequence of SEQ ID NO:2. Such polypeptides include those comprising the amino acid sequence of SEQ ID NO:2. In a

25 most preferred aspect the polypeptide has the amino acid sequence of SEQ ID NO:2.

Polypeptides useful in the present invention will possess the β -lactam synthetase activity. In one aspect, modified polypeptides may be employed which increase the titres of compounds of formula (I) or (IV) or downstream products.

In a further preferred embodiment the process of the invention includes

5 contacting the compound of formula (II) or formula (III) with a β -lactam synthetase enzyme purified from the natural source, for example from *Streptomyces clavuligerus* in a cell-free environment. A process according to the invention for preparing an enzyme having β -lactam synthetase activity comprises the steps:

- a) culturing *Streptomyces clavuligerus*,
- 10 b) harvesting and lysing the mycelium, and
- c) isolating a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2 and having β -lactam synthetase activity.

A cell-free extract is produced, preferably by sonication or other disruption of
15 the microorganisms, optionally thereafter removing cell debris, leaving the β -lactam synthetase enzyme in solution. This solution is then fractionated to isolate the β -lactam synthetase enzyme. The enzyme may be prepared by culturing the microorganism in a conventional manner, especially under aerobic conditions in a suitable liquid or semi-solid medium. In general, carbon and nitrogen sources which microorganisms can
20 assimilate and inorganic salt nutrients essential for the growth of the microorganisms are included in the culture medium.

The culture medium should contain a source of metal ions such as, for example, iron. The culture conditions may be a temperature in the range of from 10°C to 80°C and pH in the range of from 3 to 10. Preferred conditions are from 20°C to 30°C at a pH
25 of from 5 to 9, suitably, for example, about pH 7, for 0.5 to 5 days.

The enzyme may be isolated and used in purified form, partially purified form, as obtained in an impure state, as a filtrate from a disrupted cell preparation, or as a crude cell homogenate. The enzyme can be recovered and purified from the disrupted cell preparation by well-known methods including ammonium sulfate or ethanol precipitation,
30 acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high

individual stereoisomers by conventional means, for example by the use of an optically active salt as a resolving agent or by stereoselective removal of a protecting group using a suitable enzyme, for example an esterase such as subtilisin. In mixtures of diastereoisomers of the compounds the ratio of diastereoisomers may be changed by

5 treatment with a non-nucleophilic base, for example 1,5-diazabicyclo[4.3.0]non-5-ene.

Suitable optically active compounds which may be used as resolving agents are described in 'Topics in Stereochemistry', Vol. 6, Wiley Interscience, 1971, Allinger, N.L. and Eliel, W.L., Eds.

10 Alternatively, any enantiomer of a compound of formula (I) may be obtained by stereospecific synthesis using optically pure starting materials of formula (II) of known configuration.

Instead of employing a cell-free system, the process of this invention may also be operated using an intact host microorganism expressing the β -lactam synthetase enzyme through recombinant means, under conditions enabling conversion of the compound of formula (II) to the β -lactam compound of formula (I). The precursor compound of
15 formula (II) or (III), or salt thereof, is provided and contacted with the microorganism to produce the compound of formula (I) or (IV) respectively, or salt thereof. The microorganism may be in the form of a growing culture, resting culture, washed mycelium, immobilised cells, or protoplasts.

20 In a further embodiment a cell-free system, derived from the recombinant organism, may be used to carry out the process of the invention. The cell-free extract may be prepared, and the enzyme purified, as hereinbefore described.

The β -lactam synthetase polypeptides useful in the present invention may be prepared by the use of β -lactam synthetase polynucleotides. Such polynucleotides include
25 isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 95% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have 97-99% identity are highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

30 The invention also provides the use of polynucleotides which are complementary to the above described polynucleotides.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques from natural sources such as genomic DNA libraries, PCR from genomic DNA or can be synthesized using well known and commercially available techniques. Certain polynucleotides of the invention and the β -lactam synthetase polypeptides encoded by them are obtainable from *Streptomyces* species. In a preferred aspect the polynucleotides and polypeptides of the invention are obtainable from *Streptomyces clavuligerus*.

The polynucleotides used in the present invention may be DNA or alternatively RNA.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from recombinant host cells comprising recombinant expression vectors. A process of the invention for preparing an enzyme having β -lactam synthetase activity comprises the steps:

- a) culturing a host microorganism transformed with a recombinant vector comprising a polynucleotide capable of producing the polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity, and
- b) isolating the polypeptide as defined in (a).

In a further aspect, the present invention provides a recombinant vector comprising a polynucleotide capable of producing a β -lactam synthetase polypeptide when said recombinant vector is present in a compatible host. Compatible hosts include, but are not limited to, *E.coli* and *Streptomyces* species.

Cell-free translation systems can also be employed to produce such proteins using RNA polynucleotides.

Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al, Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

A great variety of expression vectors can be used, for instance, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids or from bacteriophages. The expression vectors may contain control regions that regulate as well as engender expression. Generally, any vector which is able to maintain, propagate or express

a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression vector by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (*supra*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

In a further aspect the host cell contains a high copy number of the β -lactam synthetase polynucleotide.

10 Culture of the recombinant host microorganism and isolation of the polypeptide are as described above.

The following definitions are provided to facilitate understanding of certain terms used frequently herein.

15 "β-lactam synthetase activity or β-lactam synthetase polypeptide activity" or "biological activity of the β-lactam synthetase or β-lactam synthetase polypeptide" refers to the enzyme activity which is capable of catalysing the conversion of compound (II) to (I), and in a preferred embodiment the conversion of compound (III) to (IV).

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

25 "Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, 30 double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNAs or RNAs containing one

or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications has been made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications.

"% identity", as known in the art, is a measure of the relationship between two polypeptide sequences or two polynucleotide sequences, as determined by comparing their sequences. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. The alignment of the two sequences is examined and the number of positions giving an exact amino acid or nucleotide correspondence between the two sequences determined, divided by the total length of the alignment and multiplied by 100 to give a % identity figure. This % identity figure may be determined over the whole length of the sequences to be compared, which is particularly suitable for sequences of the same or very similar length and which are highly homologous, or over shorter defined lengths, which is more suitable for sequences of unequal length or which have a lower level of homology.

Methods for comparing the identity of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs

5 BESTFIT and GAP, may be used to determine the % identity between two polynucleotides or two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences which are

10 dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences which are approximately the same length and an alignment is expected over the entire length. Preferably, the

15 parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, respectively. Preferably, % identities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and

20 FASTA (Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package). Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

30 Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a polynucleotide or a

polypeptide sequence of the present invention, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value.

Examples

- 5 All general procedures and recipes for buffers and media were carried out as described in "Molecular Cloning:- A Laboratory Manual", Sambrook, Fritsch and Maniatis, 2nd edition, Cold Spring Harbour laboratory Press (1989).

1) Construction of the vector pBLS1

- 10 1.1 Preparation of digested vector:

DNA of the plasmid vector pYZ4 (Zhang & Broome-Smith Gene 1996 p51-57, 1990) was prepared from an *E.coli* culture using standard plasmid miniprep techniques. To 9µl of this miniprep sample was added 1.5µl of EcoRI, 1.5µl KpnI, 1.5µl x10 reaction buffer supplied by the manufacturer and 1.5µl H₂O and the sample digested for 2 hours at 15 37°C. The enzymes were extracted with phenol/chloroform and the DNA isolated by ethanol precipitation. The DNA pellet was resuspended in 4µl TE.

1.2. Preparation of the 4.1kb EcoRI/KpnI DNA fragment containing orf3:

- 20 DNA of a cosmid containing the 11.6kb EcoRI fragment described in Canadian patent application no. 2108113 was prepared from an *E.coli* culture using standard miniprep techniques. To 9µl of this miniprep sample was added 1.5µl of EcoRI, 1.5µl KpnI, 1.5µl x10 reaction buffer and 1.5µl H₂O and the sample digested for 2 hours at 37°C. The enzymes were extracted with phenol/chloroform and the DNA isolated by ethanol precipitation. The pellet was resuspended in 4µl TE.

25

1.3. Ligation:

- The 4µl sample of the 4.1kb DNA fragment from example (1.2). was mixed with 4µl of digested vector from example (1.1). To this was added 1µl of x10 ligase buffer and 1µl of T4 ligase. Following incubation overnight at 4°C, 2.5µl of the solution was used to 30 transform 80µl of *E.coli* XLI-Blue competent cells (Stratagene), plated onto LB agar plates (+ kanamycin) and incubated overnight at 37°C. Miniprep DNA isolation and subsequent restriction digest analysis (BamHI/BglII, HindIII/SacI, HindIII/SphI, SalI,

BamHI/NotI) of several of the kanamycin resistant transformants confirmed that a plasmid had been obtained containing the 4.1 kb EcoRI/KpnI fragment containing orfs2 and 3 of the clavulanic acid gene cluster. This plasmid was named pBLS1.

5 **2) Construction of the vector pBLS2**

2.1. Preparation of digested vector:

A 1.5µl sample of the pET-24d(+) expression vector (Novagen) was diluted with 9µl with H₂O. To this was added 1.5µl of BamHI, 1.5µl of x10 restriction buffer and 3.0µl H₂O and the sample was incubated for 2 hours at 37°C. The restricted vector was then
10 dephosphorylated by treating with 1U calf alkaline intestinal phosphatase (New England Biolabs), at 37°C for 1 hr. The mixture was analysed by agarose gel and a DNA fragment of 5.4Kb was isolated, finally eluting into 20µl H₂O.

2.2. Preparation of the insert fragment:

15 A 50µl sample of pBLS1 vector DNA from example (1.3) was isolated from the *dam* *E.coli* strain GM2163 (New England Biolabs). The use of this strain was essential to facilitate cleavage of the DNA by the restriction enzyme BclI. To 9µl of this was added 1.5µl BclI, 1.5µl of x10 BclI buffer, and 3.0µl H₂O before incubating at 37°C for 1 hr. The mixture was analysed by agarose gel and a DNA fragment of 2 kb isolated and
20 eluted in 10ml H₂O.

2.3. Ligation:

A 6.5µl sample of DNA prepared from example (2.2) was mixed with 1µl of DNA prepared from example (2.1). To this were added 1µl of x10 ligase buffer, 0.5µl ATP
25 (1mM) and 1 µl of T4 ligase. The mixture was incubated at 16°C, for 16 hours and 2.5 µl of the solution was used to transform 40µl of XL1-Blue competent cells (Stratagene) before being plated onto LB agar plates (+ kanamycin) and incubated overnight. Ten kanamycin resistant colonies were picked at random, grown up and the plasmid DNA isolated by miniprep. Restriction digest with SalI indicated that one clone contained the 2
30 kb BclI DNA fragment as required. This clone was analysed by further restriction digests (SmaI, Bgl II, NcoI and SalI) which generated the expected fragmentation patterns confirming that orf 3 had been cloned. This plasmid was named pBLS2.

3) PCR of orf3 fragment from pBLS2

PCR amplification of the targeted gene was carried out using standard PCR techniques.

pBLS2 miniprep DNA from example (2.3) was used as template DNA. Primers were

- 5 used at a concentration of 10 μ M in TE. The 10x ThermoPol reaction buffer used contained 200mM Tris-Cl (pH 8.8), 20 mM MgSO₄, 100mM KCl, 100mM (NH₄)₂SO₄, 1% Triton X-100. dNTP solutions were used at a concentration of 100nM.

- 10 Because the pET24a expression vector was used, the 5' primer incorporated an NdeI site in frame with the start codon and the 3' primer a BamHI site as shown below:

5' primer:

NdeI

5' G GAA TCC CAT ATG GGG GCA CCG GTT CTT C 3'

15

3' primer:

BamHI

5' CGC GGA TTC CTA GGC CGC CCC CCG CG 3'

20

The underlined portions of the primer sequences denotes coding region.

The following reaction components were all added and the mixture heated to 96°C for 4 minutes before the DNA polymerase was added. The reaction mixture was overlaid with 100 μ l mineral oil before the reaction was continued.

- 25 The optimised reaction mixture contained the following:

	H ₂ O	50.5 μ l
	DMSO (50%)	20 μ l
	Buffer	10 μ l
30	MgSO ₄	2.5 μ l
	dNTPs	4 x 1 μ l
	5' Primer	1 μ l

3' Primer 1 μ l
 DNA Template 10 μ l
 Vent DNA polymerase (New England Biolabs) 1 μ l.

- 5 Temperature profile:
1. 96°C 4 min
 - then add enzyme and mineral oil
 2. 95°C 4 min
 3. 60°C, 1.5 min
 - 10 4. 72°C 2 min
 5. 95°C 1 min
 6. 60°C, 1.5 min
 7. 72°C 2 min
 8. 25 cycles of steps 5 to 7
 - 15 9. 95°C 1 min
 10. 60°C 1.5min
 11. 72°C 10 min
 12. 4°C incubate
- 20 The expected PCR product (1.5kb) was isolated from agarose gel and eluted into 30 μ l TE.
- 4) Construction of the vector pBLS3.**
- 4.1. Preparation of digested vector:
- 25 A 45 μ l sample of the pET-24a(+) expression vector (Novagen) isolated by DNA miniprep was digested using 4 μ l BamHI, 4 μ l NdeI and 6 μ l of x10 reaction buffer. The mixture was incubated at 37°C for 18 hrs and 5 μ l was analysed by agarose gel electrophoresis. The DNA fragment at 5.4kb was isolated and eluted into 5 μ l of TE.
- 30 4.2. Preparation of the insert fragment:
- 30 μ l of the orf3 PCR product from example (3) were digested with 3 μ l BamHI, 3 μ l NdeI, with 4 μ l of x10 reaction buffer. The mixture was incubated at 37°C for 18 hrs and

all of the mixture analysed by agarose gel electrophoresis. A DNA fragment corresponding to a size of 1.5kb was isolated, and eluted in 5µl H₂O.

4.3. Ligation:

- 5 A 1.0µl sample of DNA from example (4.2) was mixed with 3.0 µl of DNA from example (4.1). To this was added 1µl of x10 ligase buffer, 1.0µl ATP (1mM), 1.0µl of T4 ligase and 3.0µl of H₂O. The mixture was incubated at 23°C for 2 hours then at 16°C, for 16 hours. The mixture (5µl) was transformed into 100µl XL1-Blue before being plated onto LB agar plates (+ kanamycin) and incubated overnight at 37°C.
- 10 Miniprep DNA isolation and subsequent restriction digest analysis of several of the kanamycin resistant transformants confirmed that the expected plasmid had been obtained containing the 1.5kb PCR generated fragment containing orf3. As further confirmation, the DNA sequence of the cloned PCR product was confirmed. This plasmid was named pBLS3.

15

5) Isolation of Protein from *E.coli* fermentations

- A 50µl sample of pBLS3 vector DNA from example (4) was isolated from a 1.5ml culture of XL1- Blue(pBLS3). To 100µl of *E.coli* BL21(DE3) competent cells (New England Biolabs) were added 5µl of this mini prep DNA. The cells were then used to
- 20 inoculate LB agar plate (+ kanamycin) and the plates were incubated overnight at 37°C.

5.1. Small scale

- A single colony of *E.coli* BL21(DE3) containing pBLS3 was used to inoculate 5ml of LB containing Kanamycin. This was grown at 37°C for 4 hours, then 2ml were used to
- 25 inoculate 100mls of 2YT (+ kanamycin) and left to grow for another 2 hours at 37°C. The cultures were then induced with IPTG to a level of 0.1mM, and left to grow at 37°C overnight (17 hours) before being harvested by centrifugation at 4°C and stored at -20°C.

30 5.2. Large Scale

Larger scale fermentation was achieved by using a single colony of *E.coli* BL21(DE3) containing pBLS3 to inoculate 200ml 2YT which was grown overnight at 37°C. 10ml of

this was used to inoculate 500ml of 2YT and grown for 5 hours before being induced to a level of 0.1mM IPTG and left to grow for a further 4 hours before being harvested as before.

5 6) Purification of the orf3 protein

6.1 Sample preparation

- The volumes of the buffers used were scaled according to the weight of cells to be processed. Typically 30g of cells (prepared as described in example (5)) were resuspended in 90ml Lysis buffer; 50mM Tris-HCl (pH8), 100mM NaCl, 10% glycerol, 10 2mM DTT, 3mM EDTA. Then lysozyme was added to produce a final concentration of 0.5mg/ml and the mixture stirred for 20 minutes at 4°C. The cells were then lysed using a sonicator (5 x 10 seconds). 15mM MgCl₂ and 20µg/ml DNaseI were then added and the mixture stirred for another 15 minutes at 4°C. The mixture was then centrifuged for 30 minutes at 20,000rpm at 4°C. The supernatant was removed and 0.05% polyethylimine 15 and 1% streptomycin added. The mixture was then stirred for 20 minutes at 4°C to precipitate out the DNA which was removed by centrifugation at 20,000rpm at 4°C for 25 minutes. The supernatant was filtered before being mixed with 150ml of buffer (buffer A for FPLC described in example 6.2) ready for loading onto the FPLC system.

20 6.2 FPLC Set-up

FPLC was carried out on a Pharmacia LCC-500 plus gradient controller with a P-500 pump and Pharmacia FRAC-200 rotary fraction collector. Elution of proteins was monitored by U.V. absorption at 280nm.

ColumnQ Sepharose, 100ml

- | | | |
|----|-----------|--|
| 25 | Buffer A | 25mM Tris-HCl(pH 8.), 2mM DTT, 1mM EDTA |
| | Buffer B | 25mM Tris-HCl(pH8.0), 2mM DTT, 1mM EDTA, 2M NaCl |
| | Gradient | 0 - 8% B over 50ml at 8ml/min |
| | | 8 - 18% B over 500ml at 8ml/min |
| | Fractions | 10ml fractions collected |

- 30 Using this system 50 x 10ml fractions were collected. Analysis by SDS-PAGE gel indicated that the fractions containing orf 3 were 13 to 23. This was confirmed by further analysis of these extracts by Western blot analysis using an anti-orf3 polyclonal antibody

raised against a 16 amino acid peptide corresponding to a region close to the C-terminus of the predicted orf3 protein (VGGGRHPSEVDTDDVC) (Canadian patent application no. 2108113) which gave a positive result for the 56 KDa protein corresponding to the predicted size of the orf3 protein.

- 5 From SDS-PAGE gel analysis of the protein fractions collected by this method it was estimated that the best fractions containing orf3 were ca. 40% pure.

As a final confirmation of the orf3 protein N-terminal amino acid sequencing was undertaken using standard Edman degradation methodology. The sequence generated from this showed 100% sequence identity with the predicted sequence (Figure 12 in

- 10 Canadian patent application no. 2108113), ie.

NH₂-GAPVLPAAFGLASARTGGG

7) Assays for functionality of orf3 protein

- The crude extracts prepared from the recombinant *E. coli* containing the pBLS3vector (example 5) and the purified protein product (example 6) were tested for the ability to catalyse the conversion of the compound (III) to compound (IV). Both compound (III) and compound (IV) were prepared synthetically following previously published methods (Baldwin et al J.Chem Soc. Chem Comm. 1993 p500-2 and Elson et al J. Chem Soc. Chem Comm. 1993 p1212-4).

20

7.1

Protein extracts were assayed for the conversion of compound (III) to compound (IV) under the following conditions:

25	Assay mix	Enzyme* (ca.3mg/mL)	150ml
		Compound (III)(1M)	10ml
		MOPS (1M, pH7.4)	20ml
		Mg(AcO) ₂ (1M)	5ml
		ATP (0.5M)	5ml

- * negative controls were: 150ml extract fractions containing no orf3 protein or 150ml water.
- 30

The above mixture was heated at 37 °C for 15 minutes before being analysed by the HPLC methods described below .

7.2 Underivitisised HPLC assay conditions.

- 5 This assay was carried out using the following equipment and conditions

Waters 746 data module

Waters 600E system controller

Waters 712 WISP injector

Waters 848 tunable absorbance detector

- 10 Column ODS, 250mm x 1mM

Mobile phase H₂O

Flow rate 4ml/min

Detection 218nm

Sample injected 200ul

- 15 When extracts were used in this assay which had been shown to contain the orf3 protein (as described in example (6)) a peak was seen at 10.94 mins on the HPLC trace which correlated with the retention time for compound (IV). This peak was not detected if compound (III), ATP or the orf3 containing protein extract was omitted from the assay. The peak could also not be detected if other protein extracts, which did not contain the orf3 protein, were collected from the FPLC and assayed by the same method.

- 20 The peak identified at 10.94 mins was manually collected and submitted for electrospray mass spectrometry analysis where it was shown to have a molecular weight of 229, which is the positive ion equivalent of compound (IV). For final confirmation that this peak corresponded to compound (IV) several samples of the peak were combined, freeze dried and submitted for 500MHz nmr analysis. The spectrum produced in this test was consistent with the product of the reaction being compound (IV).

7.3 Benzoin derivatised HPLC Assay Conditions

- 30 The protocol used was Kai et al. (M. Kai, T. Miyazaki, M. Yamaguchi, Y. Ohkura, J.Chromatog. 268, 417-424, 1983) which assays for compounds containing guanidino functionalities using a fluorescence detector. The following equipment and conditions were used:

Waters 746 data module

Waters 600E system controller

Waters 712 WISP injector

Waters 848 tunable absorbance detector

5 Jasco FP-920 intelligent fluorescence detector

Column Phenyl 250x4.6mm

Buffer A Methanol : Water : 0.5M Tris-HCl(pH8.5) 50:35:15

Buffer B Methanol : Water : 0.5M Tris-HCl(pH8.5) 80:5:15

Program	Time	Flow(ml/min)	A	B
10	0	0.8	100	0
	25	0.8	0	100
	34	0.8	0	100
	35	0.8	100	0

- 15 Reagents Benzoin solution (4.0mM)
 β -Mercaptoethanol (0.1M)-sodium sulphite (0.2M) solution
 Sodium hydroxide (2.0M)
 Tris-HCl (0.5M, pH 9.2)- Hydrochloric acid (2M)

Method

- 20 To a 200 μ l sample of the incubated assay mixture described in example (7.1) was added 100 μ l of benzoin solution and 100 μ l of β -mercaptoethanol solution. Then whilst on ice 200 μ l of NaOH was added. The mixture was then heated on a hot block at 100°C for 5 minutes and returned to ice. Whilst on ice 200 μ l of Tris-HCl solution was added. 200 μ l of this sample were then injected onto the column.

- 25 A portion of the collected fraction from the HPLC purified reaction mixture described in example (7.2) was derivatised with benzoin. This sample showed a retention time that matched with that of compound (IV). The crude reaction mixture was also derivatised with benzoin and this gave peaks correlating to unused compound (III) and the product compound (IV).

- 30 As found with the results from the underivitisied HPLC experiment from example (7.2), a peak corresponding to compound (IV) was only detected when the orf3 protein was present in the assay and not when compound (III), ATP or the orf3 containing

protein extract was omitted. Also a peak corresponding to compound (IV) could not be detected if other protein extracts which did not contain the orf3 protein were collected from the FPLC were assayed by the same method.

- 5 These results demonstrate that the orf3 product catalysis the conversion of compound (III) to compound (IV) .To reflect the fact that this reaction produces a monocyclic β -lactam the enzyme was named β -lactam synthetase 1 (BLS 1).

Abbreviations

- | | | |
|----|------|---|
| 10 | TE | Tris EDTA buffer (Sambrook et al <i>supra</i>) |
| | YT | Yeast Tryptone broth/ agar (Sambrook et al <i>supra</i>) |
| | IPTG | Isopropyl β -D-thiogalactopyranoside |
| | DTT | Dithiothreitol |
| | EDTA | Ethylenediaminetetraacetic acid |
| 15 | HPLC | High Performance Liquid Chromatography |
| | FPLC | Fast Protein Liquid Chromatography |

Sequence information.

SEQ ID NO:1

ATGGGGGCACCGGTTCTTCGGGCTGCCTTCGGGTTCTTGGCCTCCGCCCAGAACGGGCGGGGGCCGGGCCCCG
 GCCCGGTCTTCGCGACCCGGGGCAGCCACACCGACATCGACACGCCCAGGGGAGCGCTCGCTCGCGGCGAC
 5 CCTGGTGCACGCCCCCTCGGTGCGCCCCGACCGCGGTGGCGCGCTCCCTACCGGCGCGCCACCACCGCG
 GTGCTCGCCGGTGAGATCTACAACGGGACGAACTCCTCTCCGTGCTGCCCGCCGACCCGCGCCGGAGGGGG
 ACGCGGAGCTGGTCTGCGGCTGCTGGAACGCTATGACCTGCATGCCCTTCGGGCTGGTGAACGGGCGCTTCG
 GACCGTGGTGGGACCGGGGACCGGGTCTGCTCGCCACCGACACGCGGTTCCGGTGGCGCTGTACACCTGT
 GTGGCGCCGGGCGAGGTCCGGGCGTCCACCGAGGCCAAGGCGCTCGCCGCGACCGCGACCCGAAGGGCTTCC
 10 CGCTCGCGGACGCCCGCGGGTCCCGGTCTGACCGGTGTCTACCAGGTGCCCGGGGCGCCGTGATGGACAT
 CGACCTCGGCTCGGGCACCCTGTCACCCACCGCACCTGGACCCGGGCTCTCCCGCCGATCCTGCCGGAG
 GCGGAGGCCGTGCGGCGGTGCGGGCCGCGCTGGAGAAGGCCGTGCGCCAGCGGGTACCCCCCGGCGACACC
 CGTGTGGTGGTGTCTCCGGCGAATCGACTCCTCCGGGGTCCGGGCTGTGCGCACCGGGCGGCGGGGAAC
 GGACACGGTGTCCATGGGACCGACAGTCCCAAGTTCGCGAGGCCCGGGGCGGTGCTCGACCATCTGCGC
 15 ACCCGGCACCGGGAGATCACCATCCCGACCGAGCTGCTGGCGCAGCTCCCGTACGCGGTGTGGGCTCCG
 AGTCGGTGGACCGGACATCATCGAGTACCTGCTCCCCCTGACAGCGCTCTACCGGGCGCTCGACGGGCCGA
 GCGCGCATCCTCACCGGGTACGGCGCGGACATCCCCCTCGGGGGCATGCACCGCGAGGACCGGCTGCCCGCG
 CTGGACACCGTTCTCGCGCACGACATGGCCACCTTCGACGGGCTGAACGAGATGTCCCGGTGCTGTCCACGC
 TGGCGGGGCACTGGACACCCACCCGTAAGTGGGTGCTGCGCGCGCGATGGCCGACGCCCTCCCGCGGAGACC
 20 GCTCAACGGCGGCGACGCCCGGACAAGTGGGTGCTGCGCGCGCGATGGCCGACGCCCTCCCGCGGAGACC
 GTCAACGGGCCAAGCTGGGCGTCCACGAGGGCTCGGGCACCAGTCTCGTTCTCCCGGCTGCTGTGGACC
 ACGGTGTGCGCGAGGACCGCGTCCACGAGGCGAAGCGGCAGGTGGTGGCGAGCTGTTGATCTCACGGTCGG
 GGGCGGACCGCACCCCTCCGAGGTGGACACCGACGATGTGGTGGCTCCGTGGCCGACCGGACCGCGGGGG
 GCGGCCTAG

25

SEQ ID NO:2

GAPVLPAAFGFLASARTGGGRAPGPVFATRGSHTDIDTPQGRSLAATLVHAPSVAPDRAVARSLTGAPTTAV
 LAGEIYNRDELLSVLPAGPAPEGDAELVLRLLERYDLHAFRLVNGRFATVVRTGDRVLLATDHAGSVPLYTCV
 APGEVRASTEAKALAAHRDPKGFPLADARRVAGLTGVYQVPAGAVMDIDLGSCTAVTHRTWTPGLSRRILPEG
 30 EAVAAVRAALEKAVAQRVTPGDTPLVVLSSGIDSSGVAACAHRAAGELDTVSMGTDTSNEFREARAVVDHLRT
 RHREITITPTELLAQLPYAVWASESVDPDIIEYLLPLTALYRALDGPERRILTYGADIPLGGMHREDRLPAL
 DTVLAHDMATFDGLNEMSPVLSTLAGHWTTHPYWDREVLDLLVSLEAGLKRHRGRDKWVLRAAMADALPAETV
 NRPKLGVEHSGTSSFSRLLLDHGVAE DRVHEAKRQVVRELFDLTVGGGRHPSEVDTDVVRSVADRTARGA


A

35

Claims


1. A process for preparing compounds of formula (I)

5




10

wherein R is H or OH and R¹ is




- 15 and where R² = H or C₁₋₆ alkyl
by contacting a compound of formula (II)



- 20 where the variables are as defined in formula (I)
with a polypeptide having at least 95% identity to the amino acid sequence of SEQ ID
NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.


2. A process according to claim 1 for preparing a compound of formula (IV)

25



(IV)

5 wherein the compound of formula (II) is N²-(2-carboxyethyl)-(S)-arginine; formula (III)



(III)

3. A process according to claim 1 or 2 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2.
4. A process according to claim 1 or 2 wherein the polypeptide has the amino acid sequence of SEQ ID NO:2.
5. A process according to any one of claims 1 to 4 wherein the polypeptide having β -lactam synthetase activity is obtainable from *Streptomyces* species.
6. A process according to claim 5 wherein the *Streptomyces* species is *Streptomyces clavuligerus*.
7. A recombinant vector comprising a polynucleotide capable of producing the polypeptide defined in claim 1 when said vector is present in a compatible host.
8. A recombinant vector according to claim 7 comprising a polynucleotide selected from the group:

- a) a polynucleotide encoding a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;
- b) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO:1; or
- c) a polynucleotide having the polynucleotide sequence of SEQ ID NO:1.

5

9. A process according to any one of claims 1 to 6 wherein the polypeptide is expressed from a recombinant vector according to claim 7 or 8.

10. A host microorganism containing a recombinant vector of claims 7 or 8.

10

11. A host microorganism according to claim 10 which is selected from *Streptomyces*, or *E.coli*.

12. A process for preparing an enzyme having β -lactam synthetase activity which comprises the steps:

15

- a) culturing *Streptomyces clavuligerus*,
- b) harvesting and lysing the mycelium, and
- c) isolating a polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

20

13. A process for preparing an enzyme having β -lactam synthetase activity which comprises the steps:

a) culturing a host microorganism transformed with a recombinant vector according to claims 7 or 8, and

25

b) isolating the polypeptide having at least 95% identity with the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2, and having β -lactam synthetase activity.

14. A process for preparing clavulanic acid comprising preparing a compound of formula (IV) in accordance with claim 2 or any claim dependent thereon, and then

30

converting the compound of formula (IV) to clavulanic acid by treatment with an enzyme system derived from *Streptomyces clavuligerus*.

0943209 10000

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROCESS FOR PREPARING CLAVAM DERIVATIVES BY USING POLYPEPTIDES HAVING
BETA-LACTAM SYNTHETASE ACTIVITY

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 15 July 1999 as Serial No. PCT/GB99/02301
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9815666.4	Great Britain	17 July 1998	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

09743209-100501

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Zoltan Kerekes, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5024.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: BARRY BARTON

Inventor's Signature: B. Barton Date: 14/9/01

Residence: Worthing, West Sussex, England GBN

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: HEATHER JANE MCNAUGHTON

Inventor's Signature: H. J. McNaughton Date: 14/8/01

Residence: Oxford, Oxfordshire, England GBN

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

100743209.100500

3-0
Full Name of Inventor: CHRISTOPHER JOSEPH SCHOFIELD

Inventor's Signature: C.J. Schiefel Date: 12-01-01

Residence: Oxford, Oxfordshire, England GBN

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

4-0
Full Name of Inventor: JAN EDWARD THIRKETTLE

Inventor's Signature: [Signature] Date: 12-01-01

Residence: Worthing, West Sussex, England GBN

Citizenship: British

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

00443209 10501
105001 60224260

SEQUENCE LISTING

<110> Barton, Barry
McNaughton, Heather Jane
Schofield, Christopher Joseph
Thirkettle, Jan Edward

<120> Process for Preparing Clavam Derivatives
by Using Polypeptides Having Beta-Lactam Synthetase Activity

<130> P32085

<140> PCT/GB99/02301

<141> 1999-07-15

<150> GB 9815666.4

<151> 1998-07-17

<160> 6

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1542

<212> DNA

<213> Streptomyces clavuligerus

<400> 1

atggggggcac	cggttcttcc	ggctgccttc	gggttctctgg	cctccgccc	aacgggagg	60
ggccggggccc	ccggcccggg	cttcgcgacc	cggggcagcc	acaccgacat	cgacacgccc	120
caggggggagc	gctcgctcgc	ggcgaccctg	gtgcacgccc	cctcggtcgc	gcccgaaccgc	180
gcgggtggcgc	gctccctcac	cggcgcgccc	accaccgcgg	tgctcgccgg	tgagatctac	240
aaccgggacg	aactcctctc	cgtgctgccc	gccggaccgc	cgccggaggg	ggacgcggag	300
ctggtcctgc	ggctgctgga	acgctatgac	ctgcatgoc	tccggctggt	gaacgggcgc	360
ttcgcgaccg	tggtgcggac	cggggaccgg	gtcctgctcg	ccaccgacca	cgccgggttcg	420
gtgccgctgt	acacctgtgt	ggcgccgggc	gaggtccggg	cgtccaccga	ggccaaggcg	480
ctcgccgcgc	accgcgaccc	gaagggcttc	ccgctcgccg	acgcccgccg	ggtcgccggt	540
ctgaccggtg	tctaccaggt	gcccgcgggc	gccgtgatgg	acatcgacct	cggctcgggc	600
accgccgtca	cccaccgcac	ctggaccccg	ggcctctccc	gccgcatac	gccggagggc	660
gaggccgtcg	cggccgtgcg	ggccgcgctg	gagaaggccg	tcgcccagcg	ggtcaccccc	720
ggcgacaccc	cggttggtgt	gctctccggc	ggaatcgact	cctccggggg	cgcggcctgt	780

09743209 10301

Case	Age	Sex	Occupation	Duration of symptoms	Onset	Course	Outcome
1	45	Male	Farmer	10 years	1975	Chronic	Recovery
2	52	Female	Housewife	5 years	1978	Chronic	Recovery
3	38	Male	Teacher	3 years	1980	Chronic	Recovery
4	60	Female	Retired	15 years	1965	Chronic	Recovery
5	42	Male	Engineer	8 years	1972	Chronic	Recovery
6	55	Female	Manager	12 years	1968	Chronic	Recovery
7	35	Male	Student	2 years	1982	Chronic	Recovery
8	48	Female	Doctor	7 years	1976	Chronic	Recovery
9	58	Male	Lawyer	11 years	1967	Chronic	Recovery
10	40	Female	Artist	6 years	1979	Chronic	Recovery
11	50	Male	Scientist	9 years	1973	Chronic	Recovery
12	62	Female	Writer	14 years	1966	Chronic	Recovery
13	32	Male	Student	1 year	1983	Chronic	Recovery
14	44	Female	Teacher	4 years	1981	Chronic	Recovery
15	56	Male	Engineer	10 years	1971	Chronic	Recovery
16	64	Female	Manager	13 years	1969	Chronic	Recovery
17	36	Male	Student	2 years	1982	Chronic	Recovery
18	46	Female	Doctor	6 years	1977	Chronic	Recovery
19	54	Male	Lawyer	11 years	1968	Chronic	Recovery
20	41	Female	Artist	5 years	1980	Chronic	Recovery

<211> 512

<213> Streptomyces clavuligerus

Gly	Ala	Pro	Val	Leu	Pro	Ala	Ala	Phe	Gly	Phe	Leu	Ala	Ser	Ala	Arg
1				5					10					15	
Thr	Gly	Gly	Gly	Arg	Ala	Pro	Gly	Pro	Val	Phe	Ala	Thr	Arg	Gly	Ser
			20					25					30		
His	Thr	Asp	Ile	Asp	Thr	Pro	Gln	Gly	Glu	Arg	Ser	Leu	Ala	Ala	Thr
		35					40					45			
Leu	Val	His	Ala	Pro	Ser	Val	Ala	Pro	Asp	Arg	Ala	Val	Ala	Arg	Ser
	50					55				60					
Leu	Thr	Gly	Ala	Pro	Thr	Thr	Ala	Val	Leu	Ala	Gly	Glu	Ile	Tyr	Asn
65					70					75				80	
Arg	Asp	Glu	Leu	Leu	Ser	Val	Leu	Pro	Ala	Gly	Pro	Ala	Pro	Glu	Gly
			85					90					95		
Asp	Ala	Glu	Leu	Val	Leu	Arg	Leu	Leu	Glu	Arg	Tyr	Asp	Leu	His	Ala
		100						105					110		
Phe	Arg	Leu	Val	Asn	Gly	Arg	Phe	Ala	Thr	Val	Val	Arg	Thr	Gly	Asp
	115						120					125			
Arg	Val	Leu	Leu	Ala	Thr	Asp	His	Ala	Gly	Ser	Val	Pro	Leu	Tyr	Thr
	130					135					140				
Cys	Val	Ala	Pro	Gly	Glu	Val	Arg	Ala	Ser	Thr	Glu	Ala	Lys	Ala	Leu
145					150					155				160	
Ala	Ala	His	Arg	Asp	Pro	Lys	Gly	Phe	Pro	Leu	Ala	Asp	Ala	Arg	Arg
			165					170					175		
Val	Ala	Gly	Leu	Thr	Gly	Val	Tyr	Gln	Val	Pro	Ala	Gly	Ala	Val	Met

180	185	190
Asp Ile Asp Leu Gly Ser Gly Thr Ala Val Thr His Arg Thr Trp Thr		
195	200	205
Pro Gly Leu Ser Arg Arg Ile Leu Pro Glu Gly Glu Ala Val Ala Ala		
210	215	220
Val Arg Ala Ala Leu Glu Lys Ala Val Ala Gln Arg Val Thr Pro Gly		
225	230	235
Asp Thr Pro Leu Val Val Leu Ser Gly Gly Ile Asp Ser Ser Gly Val		
245	250	255
Ala Ala Cys Ala His Arg Ala Ala Gly Glu Leu Asp Thr Val Ser Met		
260	265	270
Gly Thr Asp Thr Ser Asn Glu Phe Arg Glu Ala Arg Ala Val Val Asp		
275	280	285
His Leu Arg Thr Arg His Arg Glu Ile Thr Ile Pro Thr Thr Glu Leu		
290	295	300
Leu Ala Gln Leu Pro Tyr Ala Val Trp Ala Ser Glu Ser Val Asp Pro		
305	310	315
Asp Ile Ile Glu Tyr Leu Leu Pro Leu Thr Ala Leu Tyr Arg Ala Leu		
325	330	335
Asp Gly Pro Glu Arg Arg Ile Leu Thr Gly Tyr Gly Ala Asp Ile Pro		
340	345	350
Leu Gly Gly Met His Arg Glu Asp Arg Leu Pro Ala Leu Asp Thr Val		
355	360	365
Leu Ala His Asp Met Ala Thr Phe Asp Gly Leu Asn Glu Met Ser Pro		
370	375	380
Val Leu Ser Thr Leu Ala Gly His Trp Thr Thr His Pro Tyr Trp Asp		
385	390	395
Arg Glu Val Leu Asp Leu Leu Val Ser Leu Glu Ala Gly Leu Lys Arg		
405	410	415
Arg His Gly Arg Asp Lys Trp Val Leu Arg Ala Ala Met Ala Asp Ala		
420	425	430
Leu Pro Ala Glu Thr Val Asn Arg Pro Lys Leu Gly Val His Glu Gly		
435	440	445
Ser Gly Thr Thr Ser Ser Phe Ser Arg Leu Leu Leu Asp His Gly Val		
450	455	460
Ala Glu Asp Arg Val His Glu Ala Lys Arg Gln Val Val Arg Glu Leu		
465	470	475
Phe Asp Leu Thr Val Gly Gly Gly Arg His Pro Ser Glu Val Asp Thr		
485	490	495
Asp Asp Val Val Arg Ser Val Ala Asp Arg Thr Ala Arg Gly Ala Ala		
500	505	510

<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 3
ggaatcccat atgggggcac cggttcttc 29

<210> 4
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 4
cgcggtattcc taggccgccc cccgcg 26

<210> 5
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 5
Val Gly Gly Gly Arg His Pro Ser Glu Val Asp Thr Asp Asp Val Cys
1 5 10 15

<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> PCR primer

<400> 6
Gly Ala Pro Val Leu Pro Ala Ala Phe Gly Phe Leu Ala Ser Ala Arg

105001 60241/60

1
Thr Gly Gly Gly
20

5

10

15

09743209.100504